Translation of Infinium® MethylationEPIC BeadChip analysis to develop future brain tumor diagnostics

April 7, 2017

Genomics in Oncology lecture series invites Prof. Andreas von Deimling from University of Heidelberg/DKFZ to present results using methylation analysis and next-generation sequencing in neuropathology research studies. Prof. von Deimling shares his vision on how these analyses can be applied to develop brain tumor diagnostics in the future. Learn more about Genomics in Oncology, visit our website here.

A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015.

Subscribe to the Illumina video channel 

View customer spotlight videos

View Illumina webinars

View Illumina product videos

View Illumina support videos

Share this article on